Jazz Pharmaceuticals discloses retirement plan for chief commercial officer
Samantha Pearce told the company on October 6, 2026 that she will step down as Chief Commercial Officer no later than June 30, 2027, or sooner if a successor is named.
Jazz Pharmaceuticals plc disclosed in an 8-K filing that Samantha Pearce, Executive Vice President, Chief Commercial Officer, informed the company on October 6, 2026 that she intends to step down from her Chief Commercial Officer post, with her departure set for whichever comes first: the naming of a replacement or June 30, 2027.1
The filing states that Jazz intends to begin a formal search for her replacement, looking at candidates from both inside and outside the company.1
The 8-K was filed under Item 5.02, covering officer departures and appointments. It was signed on October 9, 2026 by Neena Patil, identified in the filing as Executive Vice President and Chief Legal Officer1 of Jazz Pharmaceuticals. The company is incorporated in Ireland and trades on Nasdaq under the ticker JAZZ.
The filing does not name a successor or provide a specific timeline for the search process beyond the stated June 30, 2027 outside date for Pearce's departure.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.